Nitrazepam
| Clinical data | |
|---|---|
| Trade names | Alodorm, Apodorm, Arem, Cerson, Insoma, Insomin, Mogadon, Nitrados, Nitrazadon, Nitrosun, Nitravet, Ormodon, Paxadorm, Remnos, Epam, and Somnite |
| AHFS/Drugs.com | International Drug Names |
| Dependence liability | Physical: High Psychological: Moderate |
| Addiction liability | Moderate |
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 53–94% |
| Metabolism | Hepatic |
| Elimination half-life | 16–38 hours |
| Excretion | Renal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.005.151 |
| Chemical and physical data | |
| Formula | C15H11N3O3 |
| Molar mass | 281.271 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (what is this?) (verify) | |
Nitrazepam, sold under the brand name Mogadon among others, is a hypnotic drug of the benzodiazepine class used for short-term relief from severe, disabling anxiety and insomnia. It also has sedative (calming) properties, as well as amnestic (inducing forgetfulness), anticonvulsant, and skeletal muscle relaxant effects.
It was first synthesized in the late 1950s by a team of researchers at Hoffmann-La Roche in Switzerland. It was patented in 1961 and came into medical use in 1965.